SBIR/STTR Research Award

Multi-Component Hydrogel Containing Stabilized, Encapsulated Bacteriophages for Drug-Resistant Bacterial Infections

Award identifier a6c7bd00ee8bd9bf42aa3e5693022e158a97ff4e5206de36ba185026c235d8baAwarding agency Department of Defense · Defense Health Agency

Award amount

$249,918

Program and phase

STTR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Defense Health Agency
Recipient company
MEMSEL INC.
Proposal award date
2022-03-15
Contract end date
2022-10-14
UEI
MVL7NJZWLJ87
Solicitation number
21.C
Topic code
DHA21C-003

Research abstract

Infections due to drug resistant bacteria is of particular interest to military medics, given their implication and higher prevalence in combat wounds. Bacteriophages counter antibiotic resistant bacteria and are primarily encapsulated using liposomes or simple polymers, which require temperature-controlled preservation. This results in shorter shelf life, especially in austere conditions and limited applicability in combat conditions. We have developed multifunction, easy to apply nanofibrous hydrogels for healing wounds and injuries, especially in combat conditions. Herein, we propose to develop nanofibrous hydrogels that can not only encapsulate and stabilize viable phages, but also versatile enough to heal dermal, sub-cutaneous and deep-tissue wounds and injuries, especially those infected with drug resistant bacteria. The proposed hydrogel is intended to preserve bacteriophages at austere /non-ambient conditions. Thus, their viability will be tested at wide temperature ranges (-20°C to 45°C) for prolonged time periods (1-1.5 months) at various pH (4 to 9) conditions. The bactericidal property of the proposed phage encapsulated hydrogels will also be tested on 4 out of the 6 ESKAPE pathogens namely Enterococcus faecium (E. faecium), Staphylococcus aureus (S. aureus), Klebsiella pneumoniae (K. pneumoniae), Acinetobacter baumannii (A. baumannii) and Pseudomonas aeruginosa (P. aeruginosa). Upon successful completion of Phase I of the project, we anticipate their commercial development and subsequent Phase II and Phase III studies which will enable the medics to successfully treat wounds and injuries, infected with one or more bacteria, including the drug resistant ESKAPE pathogens in combat and other situations. Our versatile hydrogels will pave the way for an easily applicable novel technology for stable encapsulation of a wide range of bacteriophages. This technology will provide sustained release and higher therapeutic efficacy of phages, for quicker healing of infections thus significantly minimizing hospitalization time, suffering and the risk of amputation or death.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2022–2025). Reported award amounts total $499,644. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Defense

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.